NCT00636805View on ClinicalTrials.gov

Aloxi for Prevention of Chemotherapy Induced Nausea and Vomiting in Malignant Glioma Patients Receiving Irinotecan With Bevacizumab

PHASE2TerminatedINTERVENTIONAL
Enrollment

63

Participants

Timeline

Start Date

May 31, 2008

Primary Completion Date

January 31, 2013

Study Completion Date

January 31, 2013

Conditions
Brain Cancer
Interventions
DRUG

Palonosetron (Aloxi) and Dexamethasone

single i.v. , dose of palonosetron 0.25 mg, and 10mg dexamethasone infused over 15 min, administered 30 min before the first dose Irinotecan and Bevacizumab chemotherapy.

Trial Locations (1)

27710

Duke University Medical Center, Durham

Sponsors

Lead Sponsor

Duke University
All Listed Sponsors
collaborator

Eisai Inc.

INDUSTRY

collaborator

National Institute of Neurological Disorders and Stroke (NINDS)

NIH

lead

Duke University

OTHER